Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD) (NCT04627428)
A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)
🩺 Plain-English Summary (8th-Grade Level)
The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
Who can join: Review the eligibility criteria below.
Location: Retina Vitreous Associates Medical Group — Beverly Hills, California
Age range: 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Retina Vitreous Associates Medical Group — Beverly Hills, California
- Spencer Center for Vision Research — Palo Alto, California
- University of Michigan Kellogg Eye Center — Ann Arbor, Michigan
📞 Contact the Study Coordinator
Phone: 05184371111
Email: jeffreystern@luxabiotech.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Dry Age-related Macular Degeneration
- Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study — Glendale, California
- Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III) — Beverly Hills, California
- Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD — Phoenix, Arizona
- A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy) — Beverly Hills, California
- Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration — Baltimore, Maryland
Explore by condition: All Dry Age-related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.